TECX
Tectonic Therapeutic, Inc.
NASDAQ · Healthcare · Biotechnology · US
$30.76
+2.79%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 72.2M | 63.5M | 41.4M | 37.0M | 25.7M |
| SG&A Expense | 22.7M | 20.5M | 16.7M | 7.7M | 7.2M |
| General & Admin Expense | 22.7M | 20.5M | 16.7M | 7.7M | 7.2M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 94.9M | 84.0M | 58.0M | 44.6M | 32.8M |
| Cost and Expenses | 94.9M | 84.0M | 58.0M | 44.6M | 32.8M |
| Operating Income (EBIT) | (94.9M) | (84.0M) | (58.0M) | (44.6M) | (32.8M) |
| Non-Operating | |||||
| Interest Income | 9.7M | 11.3M | 4.3M | 581.0K | 149.0K |
| Interest Expense | 40.0K | 63.0K | 107.0K | 152.0K | 144.0K |
| Net Interest Income | 9.6M | 11.2M | 4.2M | 429.0K | 5.0K |
| Other Non-Op Income/Expense | 9.5M | 11.1M | 33.0K | 1.8M | 650.0K |
| Non-Operating Income (excl Interest) | (9.5M) | (11.2M) | (140.0K) | (2.0M) | (794.0K) |
| EBT (Pre-Tax Income) | (85.5M) | (72.9M) | (58.0M) | (42.8M) | (32.2M) |
| Income Tax Expense | 331.0K | 1.2M | — | — | — |
| Bottom Line | |||||
| Net Income | (85.8M) | (74.2M) | (58.0M) | (42.8M) | (32.2M) |
| Earnings from Cont. Ops | (85.8M) | (74.2M) | (58.0M) | (42.8M) | (32.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (85.8M) | (74.2M) | (58.0M) | (42.8M) | (32.2M) |
| Per Share | |||||
| Basic EPS | ($4.57) | ($4.05) | ($3.93) | ($11.59) | ($29.05) |
| Diluted EPS | ($4.57) | ($4.05) | ($3.93) | ($11.53) | ($29.05) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 19.0M | 18.3M | 14.8M | 3.7M | 3.6M |
| Diluted Shares Outstanding | 19.0M | 18.3M | 14.8M | 3.7M | 3.6M |
| Profitability Metrics | |||||
| EBITDA | (83.8M) | (71.5M) | (56.2M) | (41.2M) | (31.0M) |
| D&A | 1.6M | 1.4M | 1.6M | 1.5M | 1.0M |
| EBIT | (85.4M) | (72.9M) | (57.9M) | (42.7M) | (32.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026